Last updated: February 25, 2026
What Is the Market Status of Promethazine with Codeine?
Promethazine with codeine is a combination medication used primarily as an antitussive (cough suppressant) and antiemetic. It is classified as a Schedule V controlled substance in the United States due to its potential for abuse and dependence. The drug combines promethazine, an antihistamine, with codeine, an opioid.
While historically prescribed for cough, cold, and allergy symptoms, demand has declined in regions with tighter opioid regulations. The drug's market presence is strongest in the U.S., Canada, and some European countries, with recent shifts toward alternative therapies.
Regulatory Landscape and Market Impact
Controlled Substance Scheduling
The Drug Enforcement Agency (DEA) classifies promethazine with codeine as Schedule V in the U.S. since 1970. This classification restricts prescribing and dispensing practices, influencing market size and growth potential.
Growing Regulatory Restrictions
- The U.S. has tightened regulations on opioids to curb misuse.
- Several states have limited or banned over-the-counter sales of combination products containing codeine.
- Canada has significantly restricted OTC access, mainly requiring prescriptions for codeine-containing medications since 2016.
These policies reduce outpatient sales and drive market contraction. Similar trends are observed in Australia and European countries.
Prescriber and Public Trends
- Shift toward non-opioid cough suppressants and antihistamines.
- Increased awareness of opioid addiction risks affects prescribing behaviors.
- COVID-19 pandemic initially increased demand for cough suppressants but later saw a decline due to supply chain disruptions and regulatory actions.
Competitive Landscape
Major Manufacturers
- Purdue Pharma historically produced formulations combining promethazine with codeine.
- Generic manufacturers dominate the market, given the drug’s age and patent expirations.
Alternatives and Market Substitutes
- Dextromethorphan-based products became mainstream OTC cough suppressants.
- Non-opioid prescriptions such as benzonatate and antihistamines see increased usage.
Patent and Formulation Status
- No recent patents protect promethazine with codeine independently.
- Formulations are available in multiple dosage forms: syrup, tablets, solutions.
Market Volume and Revenue Projections
Historical Trends (2015–2022)
| Year |
Estimated global sales (USD millions) |
Notes |
| 2015 |
120 |
Widely prescribed in U.S. |
| 2018 |
90 |
Decline due to regulations |
| 2020 |
65 |
Pandemic impact |
| 2022 |
50 |
Continued restrictions |
Forecast to 2027
| Year |
Projected sales (USD millions) |
Compound Annual Growth Rate (CAGR) |
| 2023 |
47 |
|
| 2024 |
45 |
-4.4% |
| 2025 |
42 |
-4.4% |
| 2026 |
40 |
-4.8% |
| 2027 |
38 |
-5.0% |
The declining trend reflects regulatory restrictions, alternative therapies, and reduced prescribing.
Regional Market Breakdown (2022)
| Region |
Market Share |
Notes |
| North America |
60% |
Largest due to historical use |
| Europe |
20% |
Seasonal demand impacts |
| Asia-Pacific |
15% |
Limited, mainly in India and Japan |
| Rest of World |
5% |
Marginal presence |
Key Factors Affecting Future Market Trajectory
- Regulatory Restrictions: Increase in controlled substance regulations diminishes sales volume.
- Market Advancements: Growth of non-opioid alternatives reduces dependence on promethazine with codeine.
- Patent Expirations: No new patents limit innovative formulation development.
- Public Attitudes: The opioid crisis influences prescriber and patient preferences away from codeine-based therapies.
- Pandemic Effects: COVID-19 temporarily boosted cough suppression demand but normalized as restrictions eased.
Implications for Stakeholders
- Pharmaceutical Companies: Focus on developing non-opioid cough suppressants; analyze market exits or strategic positioning in regions loosening restrictions.
- Investors: Market decline indicates limited growth prospects; evaluate potential in alternative or biosimilar markets.
- Regulatory Bodies: Increased scrutiny could further restrict availability, impacting market size.
Key Takeaways
- Global sales of promethazine with codeine peaked pre-2018 but have declined due to regulatory and market shifts.
- The market is contracting at an estimated CAGR of -4.4% from 2023 to 2027.
- U.S. and Canadian markets dominate historically, with European markets increasingly restricted.
- The drug faces obsolescence due to safety concerns and availability of alternatives.
- Growth prospects are limited, emphasizing needs for innovation or market repositioning.
FAQs
1. Why have regulatory agencies limited the use of promethazine with codeine?
They aim to reduce opioid misuse and dependence, leading to tighter restrictions and declining prescriptions.
2. Are there any new formulations of promethazine with codeine being developed?
No recent patents or development initiatives are publicly known, focusing instead on alternative therapies.
3. How does the decline of promethazine with codeine affect treatment options?
Clinicians shift to non-opioid cough suppressants like dextromethorphan or antihistamines.
4. Which regions are most impacted by regulatory restrictions?
North America and Europe observe significant declines, with Asian markets less affected due to differing regulations.
5. What is the outlook for companies holding existing patents or formulations?
Most hold mature, off-patent formulations; revenue potential hinges on regulatory shifts or formulation innovations.
References
[1] U.S. Drug Enforcement Agency. (2020). Controlled Substances Schedules.
[2] Health Canada. (2016). Restrictions on Codeine-containing Medications.
[3] IMS Health. (2019). Global Sales Data for OTC and Prescription Cough Medications.
[4] European Medicines Agency. (2021). Review of Opioid-containing Medications.
[5] Statista. (2022). Market Revenue and Volume for Opioid-Containing Cough Suppressants.
